GGrantIndex
← Leaderboards

Scott Boitano

University Of Wyoming

Google Scholar ↗PubMed ↗ORCID ↗
$5,292,082
Attributed
$13,376,590
Total exposure
14
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2009–25
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,376,590 · 14

By mechanism

R01$6,462,513 · 4
R42$3,433,831 · 1
R44$1,671,055 · 1
R41$798,299 · 3
R56$439,180 · 1
R21$419,076 · 1

Top collaborators

Others in their field

Top investigators on “Pre-Clinical”

Research focus

Pre-ClinicalPharmaceutical PreparationsNovel TherapeuticsPeptide HydrolasesMouse ModelG-Protein-Coupled ReceptorsPathway InteractionsPar-2 ReceptorLigandsPharmacologyPhysiologicalIn VivoPeptidomimeticsIn VitroInflammatoryLeadValidationPlayDrug DiscoveryNociceptorsPainAdultAgonistPathology

Grant awards (31)

Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$792,665
R44 · FY2025 · HL
A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma$759,637
R01 · FY2025 · AI · contact PI
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$878,390
R44 · FY2024 · HL
A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma$716,690
R01 · FY2024 · AI · contact PI
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,478,237
R42 · FY2023 · HL
Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics$300,000
R41 · FY2023 · HL
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,955,594
R42 · FY2022 · HL
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2021 · NS
Development of Small Molecule Antagonists of PAR-2 for treatment of asthma$283,387
R41 · FY2021 · HL
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2020 · NS
Development of surfactant protein A-derived peptidomimetics for the treatment of asthma$214,912
R41 · FY2020 · HL
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2019 · NS
Development of PAR2 Antagonists for Control of Asthma$191,875
R21 · FY2019 · AI · contact PI
Protease Activated Receptor Type 2 Targeting for Migraine Pain$512,010
R01 · FY2018 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$382,151
R01 · FY2018 · NS
Development of PAR2 Antagonists for Control of Asthma$227,201
R21 · FY2018 · AI · contact PI
Protease Activated Receptor Type 2 Targeting for Migraine Pain$494,334
R01 · FY2017 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$439,180
R56 · FY2016 · NS
PAR2 targeted drug discovery for the treatment of pain$327,669
R01 · FY2015 · NS · contact PI
PAR2 targeted drug discovery for the treatment of pain$324,499
R01 · FY2014 · NS · contact PI
PAR2 targeted drug discovery for the treatment of pain$316,408
R01 · FY2013 · NS · contact PI
PAR2 targeted drug discovery for the treatment of pain$327,987
R01 · FY2012 · NS · contact PI
PAR2 targeted drug discovery for the treatment of pain$328,086
R01 · FY2011 · NS · contact PI
International Gap Junction Conference 2009$17,250
R13 · FY2009 · HL · contact PI
MODELING AIRWAY RESPONSE TO BORDETELLA SP INFECTION$184,670
R01 · FY2003 · HL
MODELING AIRWAY RESPONSE TO BORDETELLA SP INFECTION$172,970
R01 · FY2002 · HL
SPATIOTEMPORAL NITRIC OXIDE SIGNALING, AIRWAY EPITHELIUM$0
P20 · FY2002 · RR
MODELING AIRWAY RESPONSE TO BORDETELLA SP INFECTION$172,150
R01 · FY2001 · HL
SPATIOTEMPORAL NITRIC OXIDE SIGNALING, AIRWAY EPITHELIUM$0
P20 · FY2001 · RR
CA2+, GAP JUNCTIONS &COMMUNICATION IN ALVEOLAR II CELLS$135,386
R15 · FY2000 · HL
SPATIOTEMPORAL NITRIC OXIDE SIGNALING, AIRWAY EPITHELIUM$0
P20 · FY2000 · RR